Genomic correlates of outcome in a randomised comparison of CPX-351 and FLAG-Ida in high-risk acute myeloid leukaemia and myelodysplastic syndrome: results from the UK NCRI AML19 Trial
Authors
Othman, J.Dillon, R.
Wilhelm-Benartzi, C.
Knapper, S.
Batten, L. M.
Canham, J.
Hinson, E. L.
Villiers, W.
Kleeman, M.
Gilkes, A.
Potter, N.
Overgaard, U. M.
Mehta, P.
Kottaridis, P.
Cavenagh, J.
Hemmaway, C.
Arnold, C.
Dennis, Michael
Russell, N. H.
Affiliation
Department of Medical and Molecular Genetics, King's College London, LondonIssue Date
2022
Metadata
Show full item recordCitation
Othman J, Dillon R, Wilhelm-Benartzi C, Knapper S, Batten LM, Canham J, et al. Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial. Blood. 2022 Nov;140:1036-8. PubMed PMID: WOS:000893223201017.Journal
BloodDOI
10.1182/blood-2022-159433Additional Links
https://dx.doi.org/10.1182/blood-2022-159433Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2022-159433